KSQ Therapeutics indicates identification & validation of CT-1
Category: #healthcare  By Akshay Kedari  Date: 2020-02-10
  • share
  • Twitter
  • Facebook
  • LinkedIn

KSQ Therapeutics indicates identification & validation of CT-1

KSQ Therapeutics has propelled their effort to derail refractor solid tumors by growing —eTIL™—engineered tumor infiltrating lymphocyte therapies by announcing the identification and validation of CT-1. It is worth mentioning that data emanating from functional screens of two massive CRISPR-Cas9 that uses the new platform, CRISPRomics® was presented yesterday in Canada.

Chief Scientific Officer of KSQ Therapeutics Frank Stegmeler commented that they are leaving no stone unturned to discourage refractive solid tumors by introducing adoptive cell therapy as a curative treatment; however, Immunosuppressive tumor microenvironment has confined their impact. He went on to add that CRISPRomics® helps them to work in the unfriendly tumor microenvironment by enhancing T-cell’s sheer capability. Stegmeler emphasized that the identification and validation helped them come up with a portfolio of CRISPR/Cas9 eTIL™ programs which can unravel adoptive cell therapy in refractor solid tumors of PD-1.

For the record, human TILs edited from CT-1 revealed an improved production profile of cytokine, while T cells edited from CT-1 witnessed anti-tumor activity increase ten-times in vivo. The data put forth underpins the growth of eTIL™ products and helps boost TIL adoptive cell therapy’s efficacy.

As per sources familiar with the knowledge of the matter, CRISPRomics® platform of KSQ proprietary was innately used to detect the major targets in the T-cell genome which solidifies the ACT (adoptive T cell transfer therapy) position in the PD-1 refractory mouse solid tumor models. Yet to be unveiled target identified the KSQ—CT-1—has turned out instrumental for these screens.

About the company

Founded in 2015, Massachusetts-based KSQ therapeutics has been developing a portfolio meant for treating of cancer, and adoptive cell therapy, targeted therapies, adoptive cell therapy and immuno-therapies. The company has introduced High-Confidence Drug Development that is a novel approach in R&D, bringing paradigm shift in the generation of therapeutic drug candidates.

Source credit: https://ksqtx.com/news-events/ksq-therapeutics-announces-discovery-of-gene-targets-with-potential-activity-superior-to-pd-1-for-development-of-engineered-tumor-infiltrating-lymphocyte-etil-therapies-for-solid-tumors/

About Author

Akshay Kedari    

Akshay Kedari

Akshay holds a Bachelor’s degree in computer engineering. Despite having a penchant for software development and the like, Akshay took to writing as a career owing to his passion for the field. Presently, Akshay writes articles for itresearchbrief.com and a few oth...

Read More>>

More News By Akshay Kedari

Ascentage Pharma gets approval for Phase Ib/II trial of APG-1387
Ascentage Pharma gets approval for Phase Ib/II trial of APG-1387
By Akshay Kedari

Ascentage Pharma, a clinical-stage biotechnology firm developing innovative therapies for cancers, h...

VBL Therapeutics launches Phase 2 clinical trial for colorectal cancer
VBL Therapeutics launches Phase 2 clinical trial for colorectal cancer
By Akshay Kedari

VBL Therapeutics, a renowned Israeli biopharmaceutical company, reportedly announced the initiation ...

Matinas BioPharma to start Part 2 study of MAT2203 for HIV-patients
Matinas BioPharma to start Part 2 study of MAT2203 for HIV-patients
By Akshay Kedari

Matinas BioPharma, a renowned biopharmaceutical company, has reportedly announced that DSMB (Data Sa...